
National Cancer Intelligence Network Data Briefing

NCIN has produced a detailed report covering incidence, mortality and survival; the focus of this briefing is survival.


Acute myeloid leukaemia (AML) is most common in people over the age of 60 and age-standardised incidence is higher in men. Relative survival reflects the excess mortality among cancer patients, over and above the background mortality in the country or region where they live. The analyses shown in this briefing use relative survival estimated using the maximum likelihood method for individual records, developed by Estève et al (1) using the strel command in Stata version 13.

**Outcomes**

- Over the period 2001-2010 there was little or no change in the age-standardised incidence and mortality.
- Whilst relative survival amongst older adults (65+ years) diagnosed with AML was unchanged over this period, a small improvement in outcome was seen in the 25-64 year age range, with an increase in relative survival at five years amongst males and females combined from 30% (95% CI 28 to 31%) for individuals diagnosed in 2000-03 to 38% (95% CI 36 to 40%) for those diagnosed in 2008-10.

**Treatment**

- AML treatment takes several months and involves several drugs and many days in hospital. There were some alterations to the standard treatment for adults over this time and many of the patients, especially younger patients, participated in clinical trials.
- Some progress was made in identifying patients more likely to benefit from intensive chemotherapy – and those in whom this approach was likely to do more harm than good.
- New, more experimental approaches are being used in the younger patients and it is possible that allogeneic transplantation may improve outcomes.
- In older patients less toxic chemotherapy which offers a fair chance of prolonged survival with less toxicity may be selected, knowing that it will not cure the leukaemia but may extend survival.


FIND OUT MORE:

The PHE Knowledge and Intelligence Team Northern and Yorkshire is the lead KIT for haematological cancers. https://www.gov.uk/government/organisations/public-health-england

Other useful resources within the NCIN partnership:

What cancer statistics are available and where can I find them? http://www.ncin.org.uk/publications/reports/

Public Health England’s National Cancer Intelligence Network (NCIN) is a UK-wide initiative,